Abstract
Alzheimer's disease (AD) is the most common cause of dementia, however, the treatment AD options are limited and based on administration of cholinesterase inhibitors and/or memantine, affecting glutamatergic system. Presented review article summarizes current approaches in the research of novel agents for AD treatment; it is focused on the molecules reaching the clinical trials.
The most developed direction of pharmacotherapy is focused on pathologic β-amyloid (Aβ). Several perspective studies testing monoclonal Aβ antibodies and β-secretase inhibitors are ongoing.
Further, new cholinesterase inhibitors, monoamine oxidase inhibitors, anti-tau immunotherapy, agents affecting serotonin and nicotine receptors, antioxidants, and others are developed.